CD8A and type 1 diabetes mellitus: We also found nanoparticle treatment induced an increase in CD8+ T cells with an exhausted LAG-3+ phenotype, similar to the results reported in a recent phase two trial in patients at risk for development of T1D following treatment with teplizumab [27].